Apimostinel

Drug Profile

Apimostinel

Alternative Names: AGN 241660; NRX-1074

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Naurex
  • Developer Allergan; Naurex
  • Class Antidepressants; Small molecules
  • Mechanism of Action NMDA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 12 May 2017 Chemical structure information added
  • 26 Apr 2017 NRX-1074 is now called Apimostinel
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top